Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs) - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Pulmonary Pharmacology and Therapeutics Année : 2023

Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

Lutz Wollin

Résumé

The tyrosine kinase inhibitor nintedanib has been recently approved for the treatment of Interstitial Lung Diseases (ILDs) that manifest a progressive fibrosis phenotype other than Idiopathic pulmonary Fibrosis (IPF). Nintedanib reduces the development of lung fibrosis in various animal models resembling features of PF-ILD and in vitro, it inhibits the fibrosing phenotype of human lung fibroblasts (HLFs) isolated from patients with IPF. To get insight on the cellular and molecular mechanisms that drive the clinical efficiency of nintedanib in patients with non-IPF PF-ILD, we investigated its effects on the fibrosing functions of HLFs derived from patients with PF-hypersensitivity pneumonitis (PF-HP, n = 7), PF-sarcoidosis (n = 5) and pleuroparenchymal fibroelastosis (PPFE, n = 4). HLFs were treated with nintedanib (10 nM-1 μM) and then stimulated with PDGF-BB (25–50 ng/ml) or TGF-β1 (1 ng/ml) for 24–72 h to assess proliferation and migration or differentiation. At nanomolar concentrations, nintedanib reduced the levels of PDGF receptor and ERK1/2 phosphorylation, the proliferation and the migration of PF-HP, PF-sarcoidosis and PPFE HLFs stimulated with PDGF-BB. Moreover, nintedanib also attenuates the myofibroblastic differentiation driven by TGF-β1 but only when it is used at 1 μM. The drug reduced the phosphorylation of SMAD2/3 and decreased the induction of collagen, fibronectin and α-smooth muscle actin expression induced by TGF-β1. In conclusion, our results demonstrate that nintedanib counteracts fundamental fibrosing functions of lung fibroblasts derived from patients with PF-HP, PF-sarcoidosis and PPFE, at concentrations previously reported to inhibit control and IPF HLFs. Such effects may contribute to its clinical benefit in patients suffering from these irreversible ILDs.
Fichier principal
Vignette du fichier
Joannes et al-2023-Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients.pdf (814.74 Ko) Télécharger le fichier
1-s2.0-S1094553923000792-mmc1.pptx (3.44 Mo) Télécharger le fichier
1-s2.0-S1094553923000792-mmc2.pdf (189.33 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale
Licence : CC BY NC - Paternité - Pas d'utilisation commerciale

Dates et versions

hal-04303017 , version 1 (09-02-2024)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Audrey Joannes, Tom Voisin, Claudie Morzadec, Alice Letellier, Francisco Llamas Gutierrez, et al.. Anti-fibrotic effects of nintedanib on lung fibroblasts derived from patients with Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs). Pulmonary Pharmacology and Therapeutics, 2023, Pulmonary Pharmacology and Therapeutics, 83, pp.102267-102267. ⟨10.1016/j.pupt.2023.102267⟩. ⟨hal-04303017⟩
23 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More